Before EHA 2026, OPALE flags the themes likely to matter most in leukemia
With EHA 2026 taking place in Stockholm from June 11 to 14 and the late-breaking abstracts now available online, the pre-congress picture is becoming clearer. For Institut Carnot OPALE, the most useful signals are not only the headline results still to come, but the research directions already becoming actionable for translational research, clinical development, and partnership strategy in leukemia and related diseases.
Ahead of EHA 2026, Institut Carnot OPALE is encouraging leukemia-focused pharma and biotech teams to look beyond conference buzz and focus on the scientific questions that are already taking shape.
In OPALE’s pre-EHA reading, four areas deserve particular attention: measurable residual disease and smarter stratification, resistance mechanisms and disease persistence, cell- and immune-based approaches in complex hematologic settings, and the bone marrow microenvironment as a driver of treatment response. The point is not simply to identify what is new, but to understand which advances are becoming actionable for drug development, biomarker strategy, patient selection, and proof-of-concept planning.
That framing is especially relevant now. According to EHA, regular abstracts were made available online on May 12, 2026, while accepted late-breaking abstracts went online on June 2, 2026. EHA also states that late-breaking submissions are reserved for clinical or non-clinical data that were not available at the regular abstract deadline, making them an important source of near-term scientific and development signals ahead of the meeting.
OPALE’s own footprint at EHA 2026 also reflects that breadth. In the uploaded pre-read, OPALE highlights member teams appearing in author lists across topics including AML patient, disease and molecular profiling, ultra-high-sensitivity NGS-based MRD in older AML, romaciclib plus venetoclax in AML, B-cell ALL genetics, targeting leukemia-initiating cells in T-ALL, UCART22 in relapsed/refractory CD22+ B-ALL, as well as MDS and MPN-related work. The same document notes that Anne Cromer, Head of R&D Partnerships at OPALE, will be on site during EHA 2026 to discuss collaboration opportunities.
For industrial and academic partners alike, this is what makes EHA more than a congress checkpoint. It is a moment when emerging biology, translational priorities, and development strategy begin to align more concretely. OPALE’s message ahead of the meeting is clear: in leukemia and related diseases, the most valuable conversations do not start after the data land. They can start before the congress, once the right scientific signals are identified.